Companies agree up to $570m deal for C difficile drug
Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence. It is anticipated that Sebela will lead and finance the future clinical development and commercialisation activities of NTCD-M3 in North America. … Read More